Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is ImmuneOnco Biopharmaceuticals (Shanghai) PS Ratio?
ImmuneOnco Biopharmaceuticals (Shanghai)FRA:R9Z +11.52%6 PS Ratio is 8.18 as of Aug. 12, 2026, which is 86% below its 10-year median of 59.91. GuruFocus rates FRA:R9Z with a GF Score™ of 6/100. The stock has 5 warning signs investors should review. Among 930 Biotechnology companies, ImmuneOnco Biopharmaceuticals (Shanghai) ranks better than 51.08% on this metric.
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
ImmuneOnco Biopharmaceuticals (Shanghai) PS Ratio Related Terms
ImmuneOnco Biopharmaceuticals (Shanghai) PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai) PS Ratio Chart
ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
PS Ratio
0.00
0.00
0.00
24.48
14.14
ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuneOnco Biopharmaceuticals (Shanghai) PS Ratio vs Biotechnology Industry
ImmuneOnco Biopharmaceuticals (Shanghai) PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ImmuneOnco Biopharmaceuticals (Shanghai)'s Share Price of today is €0.368.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a PS Ratio of 8.18 as of Aug. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. This is 86% below median its historical median of 59.91. Over the past decade, ImmuneOnco Biopharmaceuticals (Shanghai)'s PS Ratio has ranged from 7.09 to 28,000.00. According to the industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #455 out of 930 companies in the Biotechnology industry, placing it in the top 48.9%.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s PS Ratio too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current PS Ratio of 8.18 is 86% below median its 10-year median of 59.91. Over the past 10 years, this metric has ranged from a low of 7.09 to a high of 28,000.00. The Biotechnology industry median PS Ratio is 9.60. ImmuneOnco Biopharmaceuticals (Shanghai)'s value of 8.18 is 14.8% below this industry median. Based on the distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #455 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #455 out of 930 companies for PS Ratio. This puts ImmuneOnco Biopharmaceuticals (Shanghai) in the upper half of its industry. The industry median PS Ratio is 9.60. ImmuneOnco Biopharmaceuticals (Shanghai)'s value of 8.18 is 14.8% below this benchmark. Historically, ImmuneOnco Biopharmaceuticals (Shanghai)'s own PS Ratio has ranged from 7.09 to 28,000.00 over the past decade. While the company's 10-year median is 59.91 vs. the industry median of 9.60, ImmuneOnco Biopharmaceuticals (Shanghai) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.60, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImmuneOnco Biopharmaceuticals (Shanghai)'s current PS Ratio of 8.18 is 14.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. For the Biotechnology industry, the median PS Ratio is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuneOnco Biopharmaceuticals (Shanghai)'s current PS Ratio is 8.18, which is 86% below median its own 10-year median of 59.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a current PS Ratio of 8.18. The current PS Ratio is 8.18, which is 86% below median its 10-year median of 59.91 and 14.8% below the Biotechnology industry median of 9.60. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z), the current PS Ratio is 8.18 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
6GF Score
Get the complete analysis for FRA:R9Z
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R9Z has been successfully added to your 
